HB1025
Access to investigational drugs, etc.; patient with severely debilitating condition.
Status:
In House
Latest Action:
Feb. 10, 2026
House: Subcommittee recommends laying on the table (7-Y 1-N)
Chief Patron:
Wendell Walker (R)
Session:
2026 Regular Session
Summary
As Introduced. Access to investigational drugs, biological products, and devices; patient with severely debilitating condition.
Allows a patient who has a severely debilitating condition, defined in the bill as a disease or condition that causes major irreversible morbidity, to access investigational drugs, biological products, and devices when certain criteria are met. Under current law, only a patient who has a terminal condition may access such ... (More) drugs, products, and devices. (Less)-
Bill History
- 01/14/2026 - House: Prefiled and ordered printed; Offered 01-14-2026 26102452D
- 01/14/2026 - House: Referred to Committee on Health and Human Services
- 01/23/2026 - House: Assigned sub: Health
- 02/05/2026 - House: Fiscal Impact Statement from Department of Planning and Budget (HB1025)
- 02/09/2026 - House: Placed on Health and Human Services Agenda
- 02/10/2026 - House: Subcommittee recommends laying on the table (7-Y 1-N)
